According to MedPage Today, HER2-positive gastroesophageal adenocarcinoma has entered a period of rapid therapeutic evolution. This marks a sharp contrast with the relative inactivity that characterized the field before the past five years.
The report notes that a new standard of care has been established during this period, and that this standard has already been supplanted by another. The pace of change suggests that treatment paradigms for this cancer are now shifting quickly, rather than settling into a stable approach.
Because only one source was available, there is no independent or contrasting perspective to compare. The details of specific therapies and trial data were not included in the excerpt provided.